Corrigendum to “Abrogation of constitutive stat3 activity circumvents cisplatin resistant ovarian cancer” [Cancer Lett. 341 (2013) 231–239]

doi: 10.1016/j.canlet.2013.08.022 * Corresponding author. Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China. Fax: +86 27 83662681. E-mail address: qlgao@tjh.tjmu.edu.cn (Q. Gao). 1 Note: Tengji and Danni Gong contributed equally to this work. Fig. 1. The sensitivity to cisplatin and the expression of Stat3 was compared between OV2008 and C13* ovarian cancer cells. OV2008 and C13* cells were exposed to increasing concentrations of cisplatin for 24 or 48 h. (A) Relative cell viability was determined by MTT assay after treatment with cisplatin for 48 h. (B) Apoptotic ratios increased in a dose-dependent and time-dependent manner, both in two cell lines by flow cytometry. The results represent data from three independent experiments after treatment for 24 h (C) or 48 h (D). (E) Expression of Stat3 mRNA (124 bp PCR product) was detected with RT-PCR. GAPDH (197 bp PCR product) was co-amplified as the internal control. (F) Expression of Stat3 and p-Stat3 protein was detected with Western blot analysis in total cell extracts. GAPDH was reprobed to confirm equal protein loading.